^
Association details:
| Biomarker: | KRAS overexpression |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells
Excerpt:
To determine the relevance of DDX43 expression in patients with uveal melanoma, we assessed the expression of DDX43 by RT-PCR...Similarly, levels of total KRAS and NRAS were elevated in the “nonresponder” group.
DOI:
10.1158/1535-7163.MCT-14-0095
Trial ID:
